Cargando…
Recycling side-effects into clinical markers for drug repositioning
Side-effects are the unintended consequence of therapeutic treatments, but they can also be seen as valuable read-outs of drug effects in humans; these effects are difficult to infer or predict from pre-clinical models. Indeed, some studies suggest that drugs with similar side-effect profiles may al...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334551/ https://www.ncbi.nlm.nih.gov/pubmed/22283977 http://dx.doi.org/10.1186/gm302 |
_version_ | 1782230637913047040 |
---|---|
author | Duran-Frigola, Miquel Aloy, Patrick |
author_facet | Duran-Frigola, Miquel Aloy, Patrick |
author_sort | Duran-Frigola, Miquel |
collection | PubMed |
description | Side-effects are the unintended consequence of therapeutic treatments, but they can also be seen as valuable read-outs of drug effects in humans; these effects are difficult to infer or predict from pre-clinical models. Indeed, some studies suggest that drugs with similar side-effect profiles may also share therapeutic properties through related mechanisms of action. A recent publication exploits this concept to systematically investigate new indications for already marketed drugs, and presents a strategy to get the most out of the tiny portion of chemicals that have proved to be effective and safe. |
format | Online Article Text |
id | pubmed-3334551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33345512013-01-27 Recycling side-effects into clinical markers for drug repositioning Duran-Frigola, Miquel Aloy, Patrick Genome Med Research Highlight Side-effects are the unintended consequence of therapeutic treatments, but they can also be seen as valuable read-outs of drug effects in humans; these effects are difficult to infer or predict from pre-clinical models. Indeed, some studies suggest that drugs with similar side-effect profiles may also share therapeutic properties through related mechanisms of action. A recent publication exploits this concept to systematically investigate new indications for already marketed drugs, and presents a strategy to get the most out of the tiny portion of chemicals that have proved to be effective and safe. BioMed Central 2012-01-27 /pmc/articles/PMC3334551/ /pubmed/22283977 http://dx.doi.org/10.1186/gm302 Text en Copyright ©2012 BioMed Central Ltd. |
spellingShingle | Research Highlight Duran-Frigola, Miquel Aloy, Patrick Recycling side-effects into clinical markers for drug repositioning |
title | Recycling side-effects into clinical markers for drug repositioning |
title_full | Recycling side-effects into clinical markers for drug repositioning |
title_fullStr | Recycling side-effects into clinical markers for drug repositioning |
title_full_unstemmed | Recycling side-effects into clinical markers for drug repositioning |
title_short | Recycling side-effects into clinical markers for drug repositioning |
title_sort | recycling side-effects into clinical markers for drug repositioning |
topic | Research Highlight |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334551/ https://www.ncbi.nlm.nih.gov/pubmed/22283977 http://dx.doi.org/10.1186/gm302 |
work_keys_str_mv | AT duranfrigolamiquel recyclingsideeffectsintoclinicalmarkersfordrugrepositioning AT aloypatrick recyclingsideeffectsintoclinicalmarkersfordrugrepositioning |